Drugs / LNP3794
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05187858 | Sep 2020 → Feb 2022 | — | Lupin Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LNP3794 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05187858 ↗ |
| Known as | BI3011441 | “A Phase I Open-Label Study of LNP3794 (BI3011441) in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors” NCT05187858 ↗ |
| Route | Oral | “LNP3794 capsules administered orally once daily” NCT05187858 ↗ |